PLOS ONE

RESEARCH ARTICLE

Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study

Syed Wasif Gillani[1]*, **Syed Azhar Syed Sulaiman**[2], **Vineetha Menon**[1],
Nazeerullah Rahamathullah[3], **Riham Mohamed Elshafie**[4,5], **Hassaan Anwer Rathore**[6]

1 Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, UAE, **2** Advance Medical and Dental Institute (IPPT), Universiti Sains Malaysia (USM), Penang, Malaysia, **3** Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman, UAE, **4** Clinical and Hospital Pharmacy Department, College of Pharmacy, Taibah University, Al Madinah Al Munawwarah, Saudi Arabia, **5** Clinical Pharmacy Department, ASUSH, Ain Shams University, Cairo, Egypt, **6** College of Pharmacy, QU Health, Qatar University, Doha, Qatar

* wasifgillani@gmail.com, dr.syedwasif@gmu.ac.ae

Citation: Gillani SW, Syed Sulaiman SA, Menon V, Rahamathullah N, Elshafie RM, Rathore HA (2022) Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study. PLoS ONE 17(6): e0270143. https://doi.org/10.1371/journal.pone.0270143

Editor: Raffaele Serra, University Magna Graecia of Catanzaro, ITALY

Received: January 15, 2022

Accepted: June 3, 2022

Published: June 28, 2022

Copyright: © 2022 Gillani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: DM, Diabetes Mellitus; T2DM, Type 2 Diabetes Mellitus; DPP-4, *Dipeptidyl peptidase-4*

Abstract

Objective

The aim of this study was to compare the clinical outcomes associated with different combinations of oral diabetic drugs among patients with type 2 diabetes mellitus.

Method

A prospective multicenter longitudinal, noninterventional observation study design was applied. At baseline (0 month), clinical parameters including glucose profile, renal function, lipid profile and risk assessment for cardiovascular risks were calculated. Mean Weighted difference (MWD) with heterogeneity and effect z was calculated to determine the risk reduction at the end of the study.

Results

A total of 1,657 were enrolled to different cohorts with response rate of 75.5%. The distribution of patients was based on prescribed drug. A total of 513 (30.9%) in G1 (metformin alone), 217 (13.09%) in G2 (metformin with Glimepiride), 231 (12.85%) in G3 (Metformin with Gliclazide), 384 (23.17%) in G4 (metformin with Sitagliptin) and 312 (18.89%) in G5 (Metformin with Saxagliptin). There was no significant different in all clinical and social variables at baseline. The Intergroup analysis showed significant differences with all the primary outcome variables except BMI ($p = 0.217$) and eGFR ($p = 0.782$) among patients using sulphonylurea (SU) combination (G2 & G3). Findings also showed significant high frequency of emergency visit and hospitalization in G1 (78.16% & 30.8%) as compared to SU (70.1% &

inhibitors; SU, Sulphonylurea; ASCVD, Atherosclerosis cardiovascular disease; BMI, Body Mass index; Hb1Ac, Glycated Hemoglobin; FBS, Fasting Blood sugar; PPBS, Post-prandial blood sugar; LDL, low-density lipoprotein; eGFR, estimated Glomerular-filtration rate; GI, Gastro-intestinal; HBP, High blood pressure; LBP, Low blood pressure; MWD, Mean weighted difference.

28.3%, $p = 0.001$) and DPP-4 (56.6% & 20.4%, $p = 0.001$). The overall reported effect was z = 2.58, $p = 0.001$ for ASCVD risk reduction assessment.

Conclusion

The study concluded that significant effect of *Dipeptidyl peptidase*-4 inhibitor on reduction of hospitalization, lipid profile and also ASCVD risk score of type-II diabetes mellitus patients regardless of clinical comorbidities. Also, sulfonylurea combinations have showed significant reduction in LDL and triglycerides values.

1. Introduction

Type 2 diabetes is a progressive syndrome associated with short term and long-term complications. Patients with type 2 diabetes mellitus have a high risk for cardiovascular complications like dyslipidemia, hypertension and atherosclerotic cardiovascular events and suffer from substantial morbidity and mortality [1, 2]. Worldwide projections on the prevalence of T2DM reported 70% increase in developing countries and 20% in developed countries [1, 3]. Despite effective monotherapy for diabetes, approximately 50% of patients require additional medications after 3 years to achieve target glycosylated hemoglobin (A1C) < 7% [1, 2].

Due to the progressive nature of the disease, multiple antihyperglycemic drugs like sulfonylureas and metformin are required for most patients to attain and maintain euglycemia status. Each agent offers a unique set of risk and benefit that must be considered on individualized basis [3]. Sulfonylureas stimulate insulin secretion from pancreatic beta cells independent of plasma glucose concentration and metformin is a biguanide that lowers hepatic glucose production with potential increase in insulin sensitivity. DPP-4 inhibitors like sitagliptin stabilizes the incretin peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin tropic peptide, resulting in a glucose-dependent increase in plasma insulin levels and subsequent decrease in plasma glucagon levels [3–5].

Metformin is considered as a first line drug and is efficacious in controlling glucose, insulin sensitizing and body weight effects [1, 3–5]. However, metformin has limited effect for longer duration and necessitates the use of additional drugs. Sulfonylurea (SU) drugs are often added to address this inadequacy. Glycemic control improves with the addition of SU but the efficacy is not persistent due to associated adverse events [1].

Sulfonylureas are associated with weight gain and adverse effects like hypoglycemia, which is more common among elderly than adult patients [3, 4]. Moreover, some drugs increase the hypoglycemic effect of sulfonylureas by protein displacement and reducing hepatic metabolism or decreasing urinary excretion requires extensive drug therapy workup [2, 3]. Treatment with sulfonylureas is also associated with fatal arrhythmias, weight gain, increased risk of QT prolongation, increased cardiovascular events and mortality compared with other glucose-lowering drugs [2–4]. The risk factors for the development of cardiovascular complications are multifactorial including unintended effects of antihyperglycemic medication on ASCVD score, weight gain and/or hypoglycemia [5, 6].

Similarly, third generation sulfonylurea like glimepiride is reported to induce Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) leading to hyponatremia (serum Na < 135 mmol/L) without dehydration, increased renal excretion of sodium (urinary Na > 20 mmol/L), low plasma osmolality (< 280 mOsm/kg) and high urinary osmolality (> 300 mOsm/kg) among patients with normal renal and adrenal function [3, 6, 7].

Other antidiabetic drugs like glimepiride and glipizide are associated with adverse effects like dizziness, syncope, headache, nausea, and increased serum levels of liver enzymes [1, 6]. Some of the rare reported adverse effects include angioedema, shock, agranulocytosis, aplastic anemia, disulfiram-like reaction, hypersensitivity, maculopapular rash, Stevens-Johnson syndrome, cholestatic jaundice, hepatic failure, accommodation disturbance (early during treatment) and others [5, 7]. The use of metformin has relatively low incidence of weight gain or hypoglycemia. The incidence of rare adverse event lactic acidosis is approximately 0.03 cases per 1000 patient, with 0.015 reported fatality and commonly associated with renal failure [3–5, 7]. Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer antidiabetics. Adverse drug events include acute renal failure, erectile dysfunction, peripheral neuropathy, renal insufficiency, and severe arthralgia [7, 9]. Acute pancreatitis are rarely reported in patients after treatment with incretin-based therapies [8].

Evidence-based practice showed intensive glycemic control reduces the development and progression of complications [7, 8]. Several treatment regimens are available to individualize treatment plan for patients with glucose intolerances. Combination therapies are often required for diabetic patients in addition to life-style modifications [8, 9]. Literature reported treatment failure among 50% of newly diagnosed patients treated with monotherapy diabetic therapy [4, 6, 7]. Individualization selection of drug and potency are the key-elements to treatment success and maintaining targeted HbA1c levels [4, 7, 8].

The therapeutic goals in the management of diabetes mellitus often focused to serum glycemic levels, therefore the prevention of cardiovascular events is seldom missed or overlooked [4–7]. Several evidences suggested efficacious role of pioglitazone in the reduction of coronary atherosclerosis compared to glimepiride [2, 3]. However, there are limited studies to support the efficacious preference of oral hyperglycemic drugs towards preferred prescribing in cardiovascular risk reduction [9]. The Food and Drug Administration (FDA) also excluded the approval of antidiabetic drugs without cardiovascular reported risk data [10]. Therefore, the clinical trials are shifted to determine the effect of new antidiabetic drugs on the prevention of cardiovascular events [10].

Majority of the antidiabetic medications are associated with several adverse effects, resulting in poor compliance and subsequent worsening of glucose intolerance. Healthcare providers and patients are required to objectively assess the risk and benefit of antidiabetic agents before developing a individualize care plan. In the present study is aimed to evaluate the clinical outcomes and ASCVD risk score among patients treated with combination of oral antidiabetic either with DPP4 inhibitors or sulfonylureas.

2. Methods

2.1 Ethical approval

The study was performed in compliance with World medical association (WMA) *declaration of Helsinki*: *Ethical principles for medical research involving human subjects amended by* 59th WMA (number PHRC/HC/11/13), 2013 Seoul, Korea. The study was approved by clinical research committee (CRC) 2017, Ministry of Health (MOH), Malaysia (NMRR-10-776-6941). The study protocol and follow-up procedure followed the Good Clinical Practice (GCP) guidelines 2017, MOH, Malaysia.

Patients agreed to join the study were require to sign a research informed consent form. Patients, who had difficulty in reading or understanding, acquire an impartial witness to explain the study protocol and follow-up procedures before participation. Patients were briefed extensively about the dropout criteria. Patients were also briefed about the voluntarily participation and leaving the study at time will not affect the usual care process.

2.2 Study design

This study is a prospective multicenter non-interventional longitudinal observational study.

2.3 Participant selection

The participants consist of all patients diagnosed with diabetes type 2 mellitus (T2DM), attending the diabetic management clinics for treatment. The eligibility criteria based on newly diagnosed diabetes (< 5 years), age > 18 years without any other systemic serious disease (e.g., arthritis, thyroid disorders, renal impairment, pregnancy, breast feeding, cancer etc), visiting primary or tertiary healthcare centers for follow-up at five different locations in Penang, Malaysia. Patients with impaired fasting blood glucose (FBS > 6 mmol/L & Hb1Ac > 6%) were eligible to participate. The FBS information was reconfirmed/proven from patient's medical records obtained during the recruitment process from the respective sites. Patients using other prescription drugs or documented immunological disorder were excluded from the study.

2.4 Study duration

The study was twenty-four months (2 year) long with ten-point of assessments (baseline 0-3-6-9-12-15-18-21-24) during January 2018 –December 2019. The longitudinal non-interventional observational study design was applied with stratification to determine the effect of different diabetic medications on primary clinical outcome variables.

2.5 Sampling technique and enrollment procedure

Patients may be self-referred or recommended by physicians or healthcare professionals from the relevant sites. All the eligible patients were thoroughly screened for the inclusion/exclusion criteria. Only eligible patients were provided information with consent form and study information sheet. Research coordinator prepared documents and provide enrollment lists from all five sites to principal investigator. The procurement and cohort distribution can be seen in Fig 1.

The participants were further stratified into five groups:

- G1 (metformin alone),
- G2 (metformin with Glimepiride),
- G3 (Metformin with Gliclazide),
- G4 (metformin with Sitagliptin)
- G5 (Metformin with Saxagliptin).

During the data collection process, all study forms were labeled with a unique study identifier for each cohort. All the collected forms and data were stored in a locked file cabinet in a locked office with access to principal investigator only. Co-researcher checked for any missing or outlier values. All the participants were monitored for 24 months (2 years), and participants were required to strictly follow-up at the scheduled time at every 3 months.

At study baseline (0 month), clinical parameters including glucose profile, renal function, lipid profile and risk assessment for ASCVD [11] were calculated. Treatment protocol and care services were standard across the sites under the supervision of research team (including principal investigator). All the scheduled assessment appointments with the study participants were closely monitored by the research team in collaboration with clinicians and nurses. For

Fig 1. Patient recruitment and follow-up process. * G1: Metformin alone, G2: Metformin + glimepiride, G3: Metformin + glyburide, G4: Metformin + Sitagliptin, G5: Metformin + Saxagliptim.

https://doi.org/10.1371/journal.pone.0270143.g001

quality assurance purpose all the follow-up data were reviewed and validated by principal investigator, so there was no clinical/methodological bias in the process.

2.6 Monitoring parameters

Body Mass index (BMI): Seca Stadiometer, as Obesity is in inclusion criteria so allowed limit = < 30kg/m². Seca nonelastic tape was used to determine waist circumference (WC). Blood

Pressure (BP): manual sphygmomanometer, three readings were taken 2 minutes apart (mean consider at baseline).

Fasting blood sugar: an enzymatic colorimetric method with glucose oxidase was used, required normal value < 5.6mmol/l.

Lipid profile: Total Cholesterol (Total-c), Triglycerides (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) were assessed by using commercially available kits.

ASCVD Criteria [11]: Risk score was used to assess the risk for the development of cardiovascular disease at baseline and end of the study. Individual score was calculated as per point system and calculate the mean for the whole cohort. Criteria: low risk (< 5%), Borderline risk (5% - 7.4%), Intermediate risk (7.5% - 19.9%), High Risk (> 20%).

2.7 Standards

BMI: Body Mass Index: (underweight: less than 18.5, healthy: 18.5–24.9, Overweight: 25–29.9).

Hb1Ac: Glycated Hemoglobin (< 6.5%), FBS: Fasting blood sugar (Normal: 4.4–7.0mmol/L, PPBS: Post-Prandial Blood Sugar, two hours after meal (Normal: 4.4–8.5mmol/L), LDL: low density lipoproteins (≤ 2.6mmol/L), HDL: High density lipoproteins (>1.0 (male) >1.2 mmol/L (female), Triglyceride (≤1.7mmol/L) and eGFR normal: 90 mL/min/1.73m^2.

All the participants had the access of 24/7 emergency helpline: for reporting of any adverse drug reaction/event or side effect. The clinical examination was conducted for the possible reason and documented report were submitted to principal investigator for validation and recording keeping.

2.8 Data collection tools and achieving [12]

A trained nurse of the health care centres drew a 7ml blood sample on each visit, stored in two polyethylene-evacuated tubes for quantitative measures (FBS, lipid profile and eGFR). All the qualitative measures were performed at the respective site of recruitment. All the participants were assured of confidentiality clause in the research protocol. Regular reminders provided to each participant's visit that they were participating on voluntarily basis and thus could decline at any time of study. All the positive efforts were added to minimize any potential bias and also to conduct this study in the most ethical manner possible.

2.9 Withdrawal criteria and dropout criteria [12]

Following are the withdrawal criteria used to identify dropouts and manage response among different cohorts.

a. Discontinue (D/c) patient follow-ups: participant withdrew consent and/or non-cooperative.

b. Participant developed condition or disease or illness that changed clinical parameters or study environment.

c. Female participants became pregnant.

d. Participants were clearly instructed to not take any other OTC drugs without informing the investigator at 24/7-helpline, if investigator somehow identified the use of any medications (OTC or prescribed) / herbal supplements / multivitamin supplements in any participant lead to instant D/c from the study.

e. Participants missed three consecutive or alternative schedule assessments.

f. Participants showed severe signs of hyperglycaemia that requires triple therapy or insulin or injectable.

Note: All the participants received a voice only monthly basis to ensure adequate adherence to study protocol.

2.10 Statistical analysis [12]

Data analysis was made using IBM SPSS Statistics, version 22 (Armok, NY). A probability of p<0.05 was considered statistically significant for all tests. Continuous variables were tested for normality; any non-normal values were categorized or transformed. All variables were analyzed using descriptive analysis. Unadjusted comparisons between study arms were made using t-tests for continuous variables or chi-square tests for discrete variables. One-way ANOVA were used to assess the difference between the groups at the baseline of randomization. Paired t-tests were used to evaluate the difference within the groups. In the intragroup analysis comparison were made between G2 Vs G3 (SU class), G4 Vs G5 (DPP4 class). To evaluate the overall clinical effect of SU and/or DPP4 class overall a longer treatment duration (2 years). Multivariate analysis was performed using the Bonferroni test. The purpose is to determine which means are significantly different, we must compare all pairs.

Note: Mean Weighted difference (MWD) with heterogeneity and effect z was calculated to determine the extent of effect on risk reduction score from baseline to end of the study, the study was aimed to compare the time and treatment effect among patients.

3. Results

3.1 Study participants and assessments

A total of 1,657 were enrolled to different cohorts with response rate of 75.5%. The distribution of patients was based on prescribed drug. A total of 513 (30.9%) in G1 (metformin alone), 217 (13.09%) in G2 (metformin with Glimepiride), 231 (12.85%) in G3 (Metformin with Gliclazide), 384 (23.17%) in G4 (metformin with Sitagliptin) and 312 (18.89%) in G5 (Metformin with Saxagliptin). The patients' recruitment process and distribution pattern are provided in Fig 1. A total of 1627 (98.18%) completed the study follow-up and included for final assessment and analysis.

3.2 Equity and balance at baseline

The baseline characteristics are presented in Table 1. The Findings showed no significant difference among different cohorts. Slight difference among all the cohorts was seen in frequencies of comorbidities however was not significant. All the other clinical and social parameters were also non-significant.

3.3 BMI and bodyweight pattern in the study

The BMI distribution pattern over 24 months duration showed significant difference with Group 1 ($p = 0.021$), Group 2 ($p = 0.036$) and Group 3 ($p = 0.001$). The findings showed moderate increase in BMI among three cohorts. The analysis showed that patients with sulphonylureas (SU) have significant increase in BMI as compared to metformin alone (G1) and DPP-4 (G4 & 5). The distribution pattern of BMI over 24 months is presented in Fig 2A. In comparison to the mean body weight, a change over the 24-months showed significant difference with G1 ($p = 0.001$), G3 ($p = 0.031$) and G5 ($p = 0.001$). The increment in the mean bodyweight was

Table 1. Baseline characteristics of sociodemographic and primary outcomes.

Character	G1 (n = 513)	G2 (n = 217)	G3 (n = 231)	G4 (n = 384)	G5 (n = 312)	P-value
N(%)						
Male	291 (56.7)	123 (56.7)	144 (62.3)	247 (64.3)	201 (64.4)	0.513
Female	222 (43.3)	94 (43.3)	87 (37.7)	137 (35.7)	111 (35.6)	
Mean ± S.D						
Age	36.54±1.87	35.82±3.14	36.71±2.92	37.44±2.84	36.63±2.01	0.482
BMI	24.1±2.11	25.2±1.89	23.3±1.07	24.7±2.01	23.96±2.19	0.773
Weight(kg)	75.1±1.39	76.4±1.77	80.1±2.91	74.4±1.81	79.3±1.62	0.551
Hb1Ac (%)	8.14±1.31	7.93±1.69	8.32±1.03	7.86±1.92	8.01±2.11	0.316
FBS (mmol/L)	8.32±2.11	8.19±2.43	8.82±2.06	8.04±2.29	7.96±1.89	0.128
PPBS (mmol/L)	9.51±1.78	9.72±1.99	9.33±2.03	9.41±1.89	9.28±1.76	0.341
LDL (mmol/L)	2.51±1.33	2.18±1.23	1.97±1.36	2.04±1.41	2.21±1.59	0.498
Triglycerides	1.63±1.01	1.70±1.21	1.51±1.39	1.68±1.82	1.74±162	0.613
eGFR (mL/min/1.73m^2)	91.71±1.98	90.34±0.83	92.19±1.08	91.08±1.04	92.01±1.11	0.772
Marital n(%)						
Ever	463(90.3)	182 (83.9)	197 (85.3)	341 (88.8)	296 (94.9)	0.211
Never	50 (9.7)	35 (16.1)	34 (14.7)	43 (11.2)	16 (5.1)	
Family History DM						
YES	474 (92.4)	203 (93.5)	219 (94.8)	361 (94.0)	280 (89.7)	0.342
NO	39 (7.6)	14 (6.5)	12 (5.2)	23 (6.0)	32 (10.3)	
Comorbidities						
YES	200 (39.0)	107 (49.3)	112 (48.5)	219 (57.0)	201 (64.4)	0.051
NO	313 (61.0)	110 (50.7)	119 (51.5)	165 (43.0)	111 (35.6)	

[*] G1: Metformin alone, G2: Metformin + glimepiride, G3: Metformin + glyburide, G4: Metformin + Sitagliptin, G5: Metformin + Saxagliptin. BMI: Body Mass Index (underweight: less than 18.5, healthy: 18.5–24.9, Overweight: 25–29.9), Hb1Ac: Glycated Hemoglobin, FBS: Fasting blood sugar, PPBS: Post-Prandial Blood Sugar, LDL: low-density lipoproteins, eGFR: estimated Glomerular filtration rate. Normal FBS: 4.4–7.0mmol/L. Normal PPBS: 4.4–8.5mmol/L. HbA1c: $\leq$ 6.5%. LDL: $\leq$ 2.6mmol/L, HDL: >1.0 (male) >1.2 mmol/L (female). Triglyceride: $\leq$1.7mmol/L. eGFR normal: 90 mL/min/1.73m^2.

https://doi.org/10.1371/journal.pone.0270143.t001

seen in G1 however a significant reduction was seen in G5 (p = 0.001) between 6–15 months of the study duration. The details are provided in Fig 2B.

3.4 Within group assessments of primary outcomes

The Intergroup analysis showed significant differences with all the primary outcome variables except BMI (p = 0.217) and eGFR (p = 0.782) among patients using sulphonylurea (SU) combination (G2 & G3). Low-density lipoproteins were the only primary variable that was not significant (p = 0.431) in the intergroup assessment of patients using DPP-4 combination (G4 & G5). Intra-group analysis showed significant differences in mean difference of primary outcome variables between control group (G1-metformin alone) compared to SU and DPP-4 combinations. All the detail analysis is provided in Table 2. Findings also showed significant high frequency of emergency visit and hospitalization due to more episodes of hyperglycemia in G1 (78.16% & 30.8%) as compared to SU (70.1% & 28.3%, p = 0.001) and DPP-4 (56.6% & 20.4%, p = 0.001). The Intra-group analysis between SU & DPP-4 combination reported significant difference (p = 0.001) in frequency of gastrointestinal disturbance and lethargy as reported adverse drug reaction. The detailed analysis and reported significant values are provided in Table 2.

Fig 2. a. Mean distribution of BMI over 24 months of the study. **b.** Mean distribution of body weight over 24 months of the study.

https://doi.org/10.1371/journal.pone.0270143.g002

3.5 Cardiovascular risk reduction pattern in different cohorts

The inter and intra-group analysis were also required to determine the effect of medication on the cardiovascular risk. The ASCVD risk assessment method was used to determine the

Table 2. Differential data analysis for the groups in the study (post 24 months).

Character	Metformin alone (n = 513)		p ‡	Metformin + SU (n = 448)		Metformin + DPP4 (n = 696)		p ‡	SU Vs DPP-4
	value	p-value		value	p- IG^	value	p- IG^		p-value≠
N (%)									
Male	291 (56.7)	0.441		267 (59.5)	0.121	0.317	448 (64.36)	0.021	0.001	0.001
Female	222 (43.3)			181 (40.4)			248 (35.63)			
Mean ± S.D									
BMI	24.91±1.81	-		25.39±1.43	0.217	0.001	24.52±1.77	0.022	0.343	0.001
Hb1Ac (%)	7.34±1.07	-		6.73±2.65	0.019	0.001	6.22±2.07	0.001	0.000	0.022
FBS	7.01±2.44	-		6.58±2.87	0.012	0.001	6.43±2.51	0.001	0.519	0.001
PPBS	8.32±1.09	-		8.49±1.65	0.024	0.432	8.32±1.21	0.001	0.001	0.028
LDL	2.43±0.88	-		1.93±0.79	0.001	0.001	1.88±0.65	0.431	0.001	0.014
Triglycerides	1.52±0.43	-		1.34± 0.31	0.001	0.021	1.19± 0.47	0.001	0.001	0.031
eGFR	83.42±1.62	-		92.32± 2.94	0.782	0.001	89.92±2.27	0.041	0.001	0.017
Emergency visits N(%)	401 (78.16)	-		314 (70.1)	-	0.001	394 (56.61)	-	0.001	0.001
Hospitalization * N(%)	158 (30.8)	-		127 (28.3)	-	0.034	142 (20.4)	-	0.001	0.021
ADRs Reporting[℗] N(%)									
Hypoglycemia	112 (21.8)	-		294 (65.6)	-	0.001	259 (37.2)	-	0.001	0.033
GI Disturbance	98 (19.1)	-		79 (17.6)	-	0.001	194 (27.9)	-	0.001	0.001
Loss of appetite	159 (30.99)	-		189 (42.2)	-	0.321	178 (25.6)	-	0.038	0.651
Weight gain	188 (36.6)	-		31 (6.92)	-	0.001	15 (2.2)	-	0.011	0.035
Lethargy	282 (54.97)	-		-	-	0.001	118 (16.9)	-	0.001	0.001
HBP	-	-		22 (4.91)	-	0.031	17 (2.44)	-	0.544	0.569
LBP	161 (31.4)	-		209 (46.6)	-	0.041	211 (30.3)	-	0.679	0.614

^IG: Intergroup *p*-value. SU: Sulphonylureas (both G2 & G3), DPP-4: Dipeptidyl peptidase 4 (both G4 & G5).

‡ comparison with Metformin alone (G1).

≠ comparison of control G1 with SU & DPP-4 groups.

* Hospitalization primary to diabetes (hyperglycemia etc.).

℗ Adverse drug reactions (ADRs) reported by patients during 2 years of study follow-up. GI: Gastrointestinal. HBT: High Blood pressure, LBP: Low Blood pressure.

Normal FBS: 4.4–7.0mmol/L. Normal PPBS: 4.4–8.5mmol/L. HbA1c: ≤ 6.5%. LDL: ≤ 2.6mmol/L, HDL: >1.0 (male) >1.2 mmol/L (female). Triglyceride: ≤1.7mmol/L. eGFR normal: 90 mL/min/1.73m^2.

difference between from baseline to endpoint. The findings showed signification mean reduction -1.1% (MWD: -1.02, 95%CI: -1.69 to -0.89, *p* = 0.041) in ASCVD risk score among patients using SU combination. Similarly, significant mean reduction -1.56% (MWD: -1.62, 95%CI: -2.18 to -1.02, *p* = 0.001) in ASCVD risk score was found among patients on DPP-4 combination. The overall reported effect was z = 2.58, *p* = 0.001. Table 3 presented detailed pre-post analysis of ASCVD risk.

4. Discussion

Patients with diabetes mellitus have deranged lipid profiles [12]. The use of antidiabetic medications has been associated to improved lipid profiles [13, 14]. This study reported that patients on both sulfonylureas and DPP 4 inhibitors-based combinations with metformin had improvements lipid profiles especially triglycerides and LDL over 24 months compared to baseline. Among both groups, the participants with the use of sulfonylureas had greater improvement over DPP 4 inhibitors. Our findings contrast with the findings of Kim *et al* 2013 and Nomoto *et al*, who found that the use of sulfonylureas led to significant, increase in LDL

Table 3. ASCVD risk assessment and comparison between different cohorts.

Cohorts	Weightage %	p- value	Pre (0 month)	Post (24 month)	Mean % reduction	MWD
			mean±S.D	Mean±S.D		(95% CI)
G1 –metformin (n = 513)	30.9%	0.077	6.32 ± 12.84	5.94 ± 10.11	- 0.36	- 0.31 (-0.43 to—0.07)
G2 + G3 (SU) (n = 448)	27.0%	0.041	6.41 ± 11.23	5.31 ± 9.83	- 1.1	- 1.02 (- 1.69 to– 0.81)
G4 + G5 (DPP-4) (n = 696)	42.0%	0.001	6.65 ± 11.84	5.09 ± 10.19	- 1.56	- 1.62 (- 2.18 to– 1.02)

SU: Sulphonylureas (both G2 & G3), DPP-4: Dipeptidyl peptidase 4 inhibitor (both G4 & G5).

ASVD: low risk ($< 5\%$), Borderline risk (5% - 7.4%), Intermediate risk (7.5% - 19.9%), High Risk ($> 20\%$).

MWD: Mean weighted difference, Heterogeneity = Chi^2 = 0.29, df = 2 ($p = 0.04$); I^2 = 32%

Test for overall effect = z = 2.58 ($p = 0.001$).

[15, 16]. We also found significant decrease in triglycerides in patients receiving sulfonylureas and DPP 4 inhibitors in combination metformin, which is different from the reported literature [15–17]. These contrast findings might be the difference in geographical location and lifestyle modification in the region.

There has been an improvement in the glycemic control among patients in all the study groups. Though HbA1c improved among all, a greater reduction in HbA1c from baseline was seen in patients treated with DPP4-metformin combination compared to SU-metformin showing a similar pattern of decrease as seen in studies conducted by Nomoto *et al* and Goke *et al.* [16, 18]. In contrast, there are some studies reported SU-metformin combination decreased HbA1c more than DPP-metformin combination [19, 20].

Impact on glycemic parameter (FBS), the results of our study have shown that the patients receiving SU-metformin combination had better control compared to DPP-metformin combination showing a similar pattern of results compared to others in literature [21]. In contrast, the aspect of post prandial control of glycemic control, DPP-metformin combination use led to better outcome compared to SU-metformin, similar findings are reported by Sharma *et al.* [22].

Presence of obesity and overweight increases the risk of insulin resistance in diabetic patients. Hypoglycemic agents are associated with weight gain. Our study found that patients treated with sulfonylureas, there was an increase in body weight and BMI, as found in most of the scientific literature [20, 23]. The other important finding of the study was a significant decrease in body weight and BMI among patients treated with DDP4 inhibitor-metformin combination and consistent with the findings of previous studies [17, 18, 20]. However, this study also identifies the efficacy mnemonics of different drugs in DPP4 and SU class.

Yet DPP-4 inhibitors have a better safety profile compared to sulfonylureas. Majority of the study population who developed hypoglycemia were belongs to sulfonylureas group compared to DPP 4 inhibitors, similar findings are reported in the literature [17, 23–25]. However, gastrointestinal disturbances and lethargy was seen more among patients treated with DPP4 inhibitors, showing similar findings as observed by Kim *et al.* [17]. In-group analysis of this study provided in-depth knowledge of drug mnemonics and toxicity profiling.

Patients on antidiabetic medications often reported hospital emergency visits leading to hospitalizations in some instances. It is difficult to predict the risk of hospital visits among different types of drugs. However, this study attempted to determine the number of emergency visits and hospitalizations among different groups treatment with different combinations. It was found that patients using DDP4 inhibitor-metformin compared to the sulfonylurea-metformin combination reported lower hospital visits. The reason for these findings might be due to reduced incidence of hypoglycemia with DDP4 inhibitor and their improved glycemic

control leading to fewer risks of emergency conditions like diabetic ketoacidosis [24, 26–29]. Combination of SU or DPP-4 inhibitors were prescribed more to the patients with worse comorbidities than control group (G1) metformin only. Yet, combination treatment had better outcome or improved cardiac risks. Among the sulfonylureas, Gliclazide was shown to have better cardiovascular profile [30, 31]. SAIS1 trial reported that treatments with DPP4 inhibitors have favorable effects on inflammatory mediators and oxidative stress in patients with T2DM without advanced atherosclerosis [16]. The cardiovascular risk (ASCVD) assessed and comparison among different combination of antidiabetic medications was another significant and novel finding of this study. It was found that ASCVD risk score was reduced in both groups receiving sulfonylureas or DPP- 4 inhibitor-based combination. In a recent literature also, it was reported that DDP4 inhibitor and sulfonylureas drugs lead to greater reduction in risk of CVD compared to metformin alone [21, 23].

5. Conclusion

The study findings concluded the effective role of sulfonylurea combination in reduction of LDL and triglycerides among patients with type 2 diabetes mellitus and not known serious clinical comorbidities. The study also concluded significant effect of *Dipeptidyl peptidase*-4 inhibitor on reduction of hospitalization, lipid profile and also ASCVD risk score of type-II diabetes mellitus patients regardless of clinical comorbidities. The distribution pattern suggested significant changes in primary clinical variables during first 6–15 months of therapy. Clinicians and healthcare professionals should be proactive in the management of secondary clinical sign & symptoms to maintain patient compliance and adherence.

6. Limitations of the study

As of all other studies this study also reported few limitations as follow.

a. Patients' censorship: change of medication during the study leads to censorship and thus the secondary analysis is required to identify the effect and confounding variables relative to change in regimen.

b. Lack of generalizability to Type 2 diabetic patients with other comorbidities.

c. Study didn't apply equal randomization among all participating sites.

d. Pharmacoeconomic impact of combination drugs. Cost-effective might have a influence on the prescribing practices.

Author Contributions

Conceptualization: Syed Wasif Gillani.

Data curation: Syed Wasif Gillani, Syed Azhar Syed Sulaiman, Nazeerullah Rahamathullah, Riham Mohamed Elshafie.

Formal analysis: Syed Wasif Gillani, Riham Mohamed Elshafie, Hassaan Anwer Rathore.

Investigation: Vineetha Menon.

Methodology: Syed Wasif Gillani, Syed Azhar Syed Sulaiman, Vineetha Menon.

Project administration: Syed Wasif Gillani, Syed Azhar Syed Sulaiman, Hassaan Anwer Rathore.

Software: Vineetha Menon, Nazeerullah Rahamathullah, Hassaan Anwer Rathore.

Supervision: Syed Wasif Gillani, Syed Azhar Syed Sulaiman.

Validation: Syed Wasif Gillani, Vineetha Menon.

Writing – original draft: Nazeerullah Rahamathullah, Riham Mohamed Elshafie.

Writing – review & editing: Syed Wasif Gillani, Hassaan Anwer Rathore.

References

1. Li J.; Shao Y.H.; Wang X.G.; Gong Y.; Li C.; Lu Y. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. *Endocr J.*, 2018, 65, 335–344. https://doi.org/10.1507/endocrj.EJ17-0372 PMID: 29375082

2. American Diabetes Association. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care, 2020, 43, S152–S162. https://doi.org/10.2337/dc20-S012 PMID: 31862755

3. Moses R.G.; Round E.; Shentu Y.; Golm G.T.; O'neill E.A.; Gantz I.; et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. *J Diabetes*, 2016, 8(5):701–11. https://doi.org/10.1111/1753-0407.12351 PMID: 26625270

4. Floyd J.S.; Sitlani C.M.; Avery C.L.; Noordam R.; Li X.; Smith A.V.; et al. Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. *Pharmacogenomics J*, 2018, 18(1):127–135. https://doi.org/10.1038/tpj.2016.90 PMID: 27958378

5. Nunes A.P.; Iglay K.; Radican L.; Engel S.S.; Yang J.; Doherty M.C.; et al. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. *Diabetes Obes Metab*, 2017, 19(10):1425–1435. https://doi.org/10.1111/dom.13000 PMID: 28497592

6. Adachi H.; Yanai H. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion. *Diabetes Metab.*,2015, 2, 176–177. https://doi.org/10.1016/j.diabet.2014.11.010 PMID: 25559655

7. Mohiuddin G. S.; Palaian S.; Shankar P. R.; Sam K. G.; Kumar M. Uncommon side effects of commonly used anti-diabetics: time to monitor them. *Int J Pharm Sci Res.*,2019, 10, 4145–4148.

8. Hayes J.; Anderson R.; Stephens J.W. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. *Drug Des. Devel. Ther.*, 2016, 10, 2263–2270. https://doi.org/10.2147/DDDT.S93076 PMID: 27486305

9. Nissen S. E.; Nicholls S. J.; Wolski K.; Nesto R.; Kupfer S.; Perez A.;. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA*, 2008, 299(13), 1561–1573. https://doi.org/10.1001/jama.299.13.1561 PMID: 18378631

10. Ambrosi P.; Daumas A.; Villani P.; Giorgi R. Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo. *Cardiology*, 2020, 145, 370–374. https://doi.org/10.1159/000506004 PMID: 32088710

11. Goff D. C. Jr, Lloyd-Jones D. M.; Bennett G.; Coady S.; D'Agostino R. B.; Gibbons R. Sr; et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, 2014, 63(25 Pt B), 2935–2959

12. Gillani S.W.; Sulaiman S.A.S.; Abdul M.I.M.; Baig M.R. Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12 month single blind mutlicenter randomized control trial. *Cardiovasc Diabetol.*, 2017, 16, 1–13.

13. Cha S. A.; Park Y. M.; Yun J. S.; Lim T. S.; Song K. H.; Yoo K. D.; et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. *Lipids in health and disease*, 2017, 16(1), 58:1–8. https://doi.org/10.1186/s12944-017-0443-4 PMID: 28403877

14. Derosa G.; Tritto I.; Romano D.; D'Angelo A.; Catena G.; Maffioli P. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. *Journal of clinical pharmacology*, 2019, 59(10), 1391–1399. https://doi.org/10.1002/jcph.1431 PMID: 31131461

15. Kim H. S.; Shin J. A.; Lee S. H.; Kim E. S.; Cho J. H.; Son H. Y.; et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. *Diabetes technology & therapeutics*, 2013, 15(10), 810–816. https://doi.org/10.1089/dia.2013.0038 PMID: 24050737

16. Nomoto H.; Miyoshi H.; Furumoto T.; Oba K.; Tsutsui H.; Inoue A.; et al. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). *PloS one*, 2016, 11(10), e0164255. https://doi.org/10.1371/journal.pone.0164255 PMID: 27711199

17. Kim S. S.; Kim I. J.; Lee K. J.; Park J. H.; Kim Y. I.; Lee Y. S.; et al. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. *Journal of diabetes*, 2017, 9(4), 412–422. https://doi.org/10.1111/1753-0407.12432 PMID: 27229178

18. Göke B.; Gallwitz B.; Eriksson J. G.; Hellqvist Å.; Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy.in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. *Int J Clin Pract.*, 2013, 67, 307–316. https://doi.org/10.1111/ijcp.12119 PMID: 23638466

19. Schernthaner G.; Durán-Garcia S.; Hanefeld M.; Langslet G.; Niskanen L.; Östgren C. J.; et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). *Diabetes*, *obesity & metabolism*,2015, 17(7), 630–638.

20. Arechavaleta R.; Seck T.; Chen Y.; Krobot K. J.; O'Neill E. A.; Duran L.; et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. *Diabetes*, *obesity & metabolism*, 2011, 13(2), 160–168. https://doi.org/10.1111/j.1463-1326.2010.01334.x PMID: 21199268

21. Gillani S.W.; Moosvi A.F. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus. *Curr. Pharm*. *Des*. 2020, 26(34):4315–4322. https://doi.org/10.2174/1381612826666200408095310 PMID: 32268860

22. Sharma M.; Sonawane R.; Marko J. L. Comparative study of efficacy and safety of sitagliptin versus glimepiride in patients of type-2 diabetes mellitus inadequately controlled with metformin alone. *Int J Adv Med.*, 2016, 3, 564–568.

23. Farah D.; Leme G.M.; Eliaschewitz F.G.; Fonseca M.C.M. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. *Diabetes Res Clin Pract.*, 2019, 149, 47–63 (2019). https://doi.org/10.1016/j.diabres.2019.01.025 PMID: 30710655

24. Fadini G. P.; Saragoni S.; Russo P.; Degli Esposti L.; Vigili de Kreutzenberg S.; Melazzini M.; et al. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. *Diabetes*, *obesity & metabolism*, 2017, 19(10), 1416–1424. https://doi.org/10.1111/dom.12979 PMID: 28432754

25. Vianna A.; Lacerda C. S.; Pechmann L. M.; Polesel M. G.; Marino E. C.; Faria-Neto J. R. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes. *Diabetes research and clinical practice*, 2018, 139, 357–365. https://doi.org/10.1016/j.diabres.2018.03.035 PMID: 29596951

26. Nauck M. A.; Meininger G.; Sheng D.; Terranella L.; Stein P. P.; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes*, *obesity & metabolism*, 2007, 9(2), 194–205.

27. Terauchi Y.; Yamada Y.; Ishida H.; Ohsugi M.; Kitaoka M.; Satoh J.; et al. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged $\geq$ 60 years (START-J trial). *Diabetes*, *obesity & metabolism*, 2017, 19(8), 1188–1192.

28. Hartley P.; Shentu Y.; Betz-Schiff P.; Golm G. T.; Sisk C. M.; Engel S. S.; et al. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial. *Drugs & aging*, 2015, 32 (6), 469–476. https://doi.org/10.1007/s40266-015-0271-z PMID: 26041585

29. Libianto R.; Davis T.M.; Ekinci E.I. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. *Med J Aust.*, 2020, 212, 133–139. https://doi.org/10.5694/mja2.50472 PMID: 31910303

30. Scheen A. J. Sécurité cardiovasculairedes inhibiteurs de la DPP-4 comparéeà celle des sulfamides hypoglycémiants [Cardiovascular safety of DPP-4 inhibitors compared to that of sulfonylureas]. *Revue medicale suisse*, 2018, 14(615), 1468–1472. PMID: 30136463

31. Mooradian A. D. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab.*,2009, 5, 150–159. https://doi.org/10.1038/ncpendmet1066 PMID: 19229235